Insmed Incorporated (NASDAQ:INSM) Shares Purchased by Patient Square Capital LP

Patient Square Capital LP raised its stake in Insmed Incorporated (NASDAQ:INSM) by 78.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 307,167 shares of the biopharmaceutical company’s stock after purchasing an additional 135,463 shares during the quarter. Insmed comprises approximately 7.9% of Patient Square Capital LP’s holdings, making the stock its 3rd biggest holding. Patient Square Capital LP owned approximately 0.17% of Insmed worth $21,207,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in INSM. Steward Partners Investment Advisory LLC grew its position in Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 163 shares during the period. V Square Quantitative Management LLC lifted its stake in shares of Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 248 shares in the last quarter. Spire Wealth Management purchased a new stake in shares of Insmed during the 4th quarter worth about $47,000. Smartleaf Asset Management LLC increased its position in Insmed by 98.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new stake in Insmed during the 4th quarter worth approximately $86,000.

Insider Activity at Insmed

In other Insmed news, CEO William Lewis sold 6,830 shares of Insmed stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $70.16, for a total value of $479,192.80. Following the completion of the transaction, the chief executive officer now directly owns 233,924 shares in the company, valued at $16,412,107.84. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Sara Bonstein sold 18,322 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total value of $1,471,439.82. Following the transaction, the chief financial officer now directly owns 118,863 shares of the company’s stock, valued at $9,545,887.53. This trade represents a 13.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 88,232 shares of company stock valued at $6,868,473 in the last quarter. Insiders own 3.00% of the company’s stock.

Insmed Price Performance

Shares of NASDAQ INSM opened at $65.71 on Wednesday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $11.95 billion, a price-to-earnings ratio of -11.75 and a beta of 0.84. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91. The business has a 50 day simple moving average of $72.17 and a 200-day simple moving average of $73.26.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The business had revenue of $92.82 million for the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm’s revenue for the quarter was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.06) EPS. As a group, equities research analysts expect that Insmed Incorporated will post -4.56 earnings per share for the current year.

Wall Street Analyst Weigh In

INSM has been the topic of a number of recent research reports. Guggenheim reaffirmed a “buy” rating and set a $101.00 price target on shares of Insmed in a research report on Tuesday, February 25th. Wells Fargo & Company upped their price target on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 19th. Morgan Stanley raised their price objective on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. Finally, Jefferies Financial Group assumed coverage on Insmed in a report on Tuesday. They set a “buy” rating and a $105.00 target price on the stock. One analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Insmed currently has a consensus rating of “Moderate Buy” and an average price target of $94.63.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.